ESMO E-Learning: Open Questions in the Treatment of Follicular Lymphoma
- To understand the most relevant open questions in the treatment of Follicular lymphoma.
- To be confronted with a possible treatment algorithm based on patients characteristics.
- To critically evaluate information from industry sponsored clinical trials in follicular lymphoma.
|Title||Duration||Content||CME Points||CME Test|
|Open Questions in the Treatment of Follicular Lymphoma||26 min.||35 slides||1||Take Test|
Follicular lymphoma is an indolent but usually incurable disease. The speed of progression varies among patients. Treatment for follicular lymphoma depends on the symptoms, tumour grade, age and general health. The clinician's goal to maintain a good quality of life for a prolonged time was traditionally approached either by watch and wait or with single-agent treatments. More aggressive regimens, including poly-chemotherapy, high-dose chemotherapy with stem-cell rescue and the emergence of new cytotoxic drugs have significantly improved the remission duration but could never demonstrate an impact on overall survival. In the past decade, survival of follicular lymphoma patients was improved by adding immunotherapy to the chemotherapy. Although follicular lymphoma is considered an indolent disease, patients typically relapse after therapy and experience disease progression. Currently, many possible treatment approaches for follicular lymphoma exist.
This ESMO E-Learning activity addresses the most relevant challenging questions clinicians face in their practice: is watch and wait still a relevant option? If so many treatments are available; what should be or should not be a standard first-line therapy today? Is there still a role for auto/allo-transplantation, and what is the role of maintenance therapy? This presentation is a compilation of reviewed data from clinical studies. Answers to the above open questions are additionally supported by presentation of real clinical cases. Take-home messages are drawn from currently available evidence.
The author has reported to be involved as speaker and member of the advisory board for Roche, Bayer, Celgene, Pfizer and Mundipharma